Advances in orthotopic liver transplantation have improved the surviva
l rate of both acute and chronic liver failure patients to nearly 70%.
However, the success of this treatment modality has created an intern
ational organ shortage, Many patients die while awaiting transplantati
on in part due to the minimal capacity to store viable transplantable
livers beyond 24 h, Additionally, for many areas of the world, routine
use of whole liver transplantation to treat liver disease is impracti
cal due to the demands on both financial and technical resources, Pote
ntially, these issues may be alleviated, at least in part, by the use
of liver cell transplantation or cellular-based liver assist devices,
The well-documented regenerative capacity of the liver may obviate the
need for whole organ transplantation in some instances of acute failu
re, if the patient may be provided temporary metabolic support. Althou
gh other patients ultimately may require transplantation, a longer per
iod of time to find a suitable organ for transplantation may be gained
by that supportive therapy, The field of liver cell transplantation m
ay offer solutions to patients with inherited metabolic deficiencies o
r chronic liver disease. The potential to treat an hepatic disorder by
using only a fraction of the whole liver would increase the number of
whole organs available for orthotopic liver transplantation. Research
in the fields of hepatocyte based intra- and extracorporeal Liver sup
port is providing evidence that these therapeutic modalities may ultim
ately become routine in the treatment of severe liver disease. A histo
ric overview of that technology along with its current status is discu
ssed.